Physician profile
D Cannon
NPI 1033103122
$10,228.50
in general payments reported to CMS, 2019-2025
30 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,827 · 2020: $1,834 · 2021: $1,655 · 2022: $697 · 2023: $732 · 2024: $1,145 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,823.92 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $963.16 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $952.79 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $543.31 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $479.66 | 2020-2023 | Xarelto |
| Insmed, INC. | $464.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.56 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $379.34 | 2019-2025 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $309.34 | 2020-2025 | Acthar |
| Genentech USA, INC. | $244.72 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $168.99 | 2019-2022 | |
| Abiomed | $150.00 | 2024 | Impella |
| Genzyme Corporation | $149.77 | 2021-2025 | |
| Mylan Specialty L.P. | $140.37 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $139.69 | 2019-2024 | Prolastin-C Liquid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $132.42 | 2025 | Pocket Eeg Device |
| Gilead Sciences, INC. | $130.42 | 2019-2023 | |
| Pfizer INC. | $121.58 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $78.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $71.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $69.13 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $54.50 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.11 | 2021 | |
| Viatris Specialty LLC | $42.66 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $34.62 | 2019 | |
| Mayne Pharma Commercial LLC | $33.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.64 | 2019-2020 | |
| Advanced Respiratory, INC | $27.62 | 2019-2021 | |
| Circassia INC. | $26.28 | 2020 | |
| La Jolla Pharmaceutical Company | $24.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw D Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.